Kezar Life Sciences
KZR | NASDAQ
$7.29
$0.00 (0.00%)
At close: May 8, 2026, 4:00 PM ET
Kezar Life Sciences Company Profile
Company profile explainedCompany Profile
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Christopher J. Kirk | Co-Founder, Chief Executive Officer & Director |
| Marc L. Belsky | Chief Financial Officer & Secretary |
| Jack Taunton | Co-Founder |
| John Franklin Fowler | Co-Founder & Director |
| Mark Schiller | Chief Operations Officer |
| Pichi Chiang | Senior Vice President & Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| May 21, 2026 | 15-12G | Filing |
| May 14, 2026 | EFFECT | Filing |
| May 13, 2026 | SC 13D/A | [Amend] Filing |
| May 12, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| May 12, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| May 11, 2026 | 4 | Filing |
| May 11, 2026 | 4 | Filing |
| May 11, 2026 | 4 | Filing |
| May 11, 2026 | 4 | Filing |
Kezar Life Sciences
| Country | United States |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Christopher J. Kirk |
Contact Details
4000 Shoreline Court South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | KZR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645666 |
| CUSIP Number | 49372L209 |
| ISIN Number | US49372L2097 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove KZR